[{"edinetCode":"E25678","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6461.0,"averageTemporaryStaff":524.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":41445000.0,"sharesOwendPercent":0.4598,"outstandingShares":null,"numberOfSubsidiary":33.0,"bps":8127.87,"equityRatio":0.842,"cashAndCashEquivalents":184221000000.0,"assets":771222000000.0,"currentAssets":308946000000.0,"fixedAsset":462276000000.0,"tangibleFixedAssets":97282000000.0,"intangibleFixedAssets":34372000000.0,"investmentAndOtherAssets":330620000000.0,"liabilities":106134000000.0,"currentLiabilities":58097000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":48036000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":665088000000.0,"capitalStock":621583000000.0,"capital":30000000000.0,"capitalSurplus":15272000000.0,"accumulatedEarnings":644038000000.0,"treasuryStock":-67727000000.0,"valuationAndConversionAdjustments":27875000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":279773000000.0,"costOfSales":101525000000.0,"grossProfit":178248000000.0,"sgaExpenses":146260000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":21260000000.0,"operatingIncome":31966000000.0,"nonOperatingIncome":7511000000.0,"nonOperatingExpenses":1441000000.0,"interestExpense":1000000.0,"ordinaryProfit":38036000000.0,"extraordinaryGain":4138000000.0,"extraordinaryLoss":217000000.0,"incomeBeforeTax":41956000000.0,"incomeTaxes":11750000000.0,"netIncome":30205000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":28781000000.0,"comprehensiveIncome":30184000000.0,"eps":360.18,"dilutedEps":359.92,"dividendPerShare":null,"per":25.1,"roe":0.045,"cashFlowFromOperatingActivities":40066000000.0,"depreciationAndCashflowFromOperatingActivities":10423000000.0,"cashFlowFromInvestingActivities":-1361000000.0,"cashFlowFromFinancialActivities":-8404000000.0,"changesInCashAndCashEquivalents":29952000000.0,"列1":"asr","submitDate":"2017\/6\/29","stockCode":4581,"accountingYear":"第６期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6340.0,"averageTemporaryStaff":491.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":41824000.0,"sharesOwendPercent":0.5235,"outstandingShares":null,"numberOfSubsidiary":33.0,"bps":8452.12,"equityRatio":0.843,"cashAndCashEquivalents":194364000000.0,"assets":800157000000.0,"currentAssets":362146000000.0,"fixedAsset":438011000000.0,"tangibleFixedAssets":93716000000.0,"intangibleFixedAssets":31116000000.0,"investmentAndOtherAssets":313178000000.0,"liabilities":108839000000.0,"currentLiabilities":60318000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":48521000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":691318000000.0,"capitalStock":643655000000.0,"capital":30000000000.0,"capitalSurplus":15271000000.0,"accumulatedEarnings":666920000000.0,"treasuryStock":-68536000000.0,"valuationAndConversionAdjustments":31009000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":280092000000.0,"costOfSales":97154000000.0,"grossProfit":182938000000.0,"sgaExpenses":146007000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":21150000000.0,"operatingIncome":36977000000.0,"nonOperatingIncome":7479000000.0,"nonOperatingExpenses":2316000000.0,"interestExpense":2000000.0,"ordinaryProfit":42140000000.0,"extraordinaryGain":6218000000.0,"extraordinaryLoss":288000000.0,"incomeBeforeTax":48070000000.0,"incomeTaxes":14701000000.0,"netIncome":33368000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":31679000000.0,"comprehensiveIncome":36627000000.0,"eps":396.54,"dilutedEps":396.2,"dividendPerShare":null,"per":26.38,"roe":0.0478,"cashFlowFromOperatingActivities":39852000000.0,"depreciationAndCashflowFromOperatingActivities":10154000000.0,"cashFlowFromInvestingActivities":-19908000000.0,"cashFlowFromFinancialActivities":-9867000000.0,"changesInCashAndCashEquivalents":10143000000.0,"列1":"asr","submitDate":"2018\/6\/28","stockCode":4581,"accountingYear":"第７期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":5142.0,"averageTemporaryStaff":492.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":41938000.0,"sharesOwendPercent":0.525,"outstandingShares":null,"numberOfSubsidiary":31.0,"bps":8924.23,"equityRatio":0.867,"cashAndCashEquivalents":263549000000.0,"assets":821782000000.0,"currentAssets":469781000000.0,"fixedAsset":352001000000.0,"tangibleFixedAssets":91283000000.0,"intangibleFixedAssets":24302000000.0,"investmentAndOtherAssets":236416000000.0,"liabilities":97645000000.0,"currentLiabilities":58453000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":39192000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":724137000000.0,"capitalStock":683025000000.0,"capital":30000000000.0,"capitalSurplus":14924000000.0,"accumulatedEarnings":706742000000.0,"treasuryStock":-68641000000.0,"valuationAndConversionAdjustments":29258000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":261551000000.0,"costOfSales":91206000000.0,"grossProfit":170345000000.0,"sgaExpenses":138951000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":20801000000.0,"operatingIncome":31211000000.0,"nonOperatingIncome":9774000000.0,"nonOperatingExpenses":135000000.0,"interestExpense":2000000.0,"ordinaryProfit":40851000000.0,"extraordinaryGain":42982000000.0,"extraordinaryLoss":19349000000.0,"incomeBeforeTax":64484000000.0,"incomeTaxes":14658000000.0,"netIncome":49825000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":48593000000.0,"comprehensiveIncome":48027000000.0,"eps":608.8,"dilutedEps":608.22,"dividendPerShare":null,"per":17.33,"roe":0.0701,"cashFlowFromOperatingActivities":19222000000.0,"depreciationAndCashflowFromOperatingActivities":10073000000.0,"cashFlowFromInvestingActivities":66044000000.0,"cashFlowFromFinancialActivities":-15467000000.0,"changesInCashAndCashEquivalents":69228000000.0,"列1":"asr","submitDate":"2019\/6\/27","stockCode":4581,"accountingYear":"第８期(自　2018年４月１日　至　2019年３月31日)","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.864,"cashAndCashEquivalents":null,"assets":824112000000.0,"currentAssets":478880000000.0,"fixedAsset":345231000000.0,"tangibleFixedAssets":94315000000.0,"intangibleFixedAssets":54698000000.0,"investmentAndOtherAssets":196218000000.0,"liabilities":93451000000.0,"currentLiabilities":55619000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":37831000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":730661000000.0,"capitalStock":688432000000.0,"capital":30000000000.0,"capitalSurplus":null,"accumulatedEarnings":693883000000.0,"treasuryStock":-35450000000.0,"valuationAndConversionAdjustments":23280000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":60260000000.0,"costOfSales":19037000000.0,"grossProfit":41223000000.0,"sgaExpenses":32981000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":8324000000.0,"nonOperatingIncome":2306000000.0,"nonOperatingExpenses":2981000000.0,"interestExpense":0.0,"ordinaryProfit":7649000000.0,"extraordinaryGain":6093000000.0,"extraordinaryLoss":3000000.0,"incomeBeforeTax":13740000000.0,"incomeTaxes":2414000000.0,"netIncome":11325000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":11006000000.0,"comprehensiveIncome":5301000000.0,"eps":137.91,"dilutedEps":137.77,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/8","stockCode":4581,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":41869000.0,"sharesOwendPercent":0.5241,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.848,"cashAndCashEquivalents":153221000000.0,"assets":843816000000.0,"currentAssets":343623000000.0,"fixedAsset":500193000000.0,"tangibleFixedAssets":112940000000.0,"intangibleFixedAssets":197291000000.0,"investmentAndOtherAssets":189961000000.0,"liabilities":109582000000.0,"currentLiabilities":66159000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":43422000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":734234000000.0,"capitalStock":692427000000.0,"capital":30000000000.0,"capitalSurplus":null,"accumulatedEarnings":697862000000.0,"treasuryStock":-35435000000.0,"valuationAndConversionAdjustments":22883000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":132208000000.0,"costOfSales":44383000000.0,"grossProfit":87825000000.0,"sgaExpenses":73260000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":10669000000.0,"operatingIncome":14676000000.0,"nonOperatingIncome":3636000000.0,"nonOperatingExpenses":3338000000.0,"interestExpense":16000000.0,"ordinaryProfit":14975000000.0,"extraordinaryGain":6098000000.0,"extraordinaryLoss":118000000.0,"incomeBeforeTax":20954000000.0,"incomeTaxes":5684000000.0,"netIncome":15270000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":14979000000.0,"comprehensiveIncome":8694000000.0,"eps":187.68,"dilutedEps":187.47,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":22455000000.0,"depreciationAndCashflowFromOperatingActivities":4942000000.0,"cashFlowFromInvestingActivities":-127792000000.0,"cashFlowFromFinancialActivities":-5308000000.0,"changesInCashAndCashEquivalents":-110327000000.0,"列1":"q2r","submitDate":"2019\/11\/13","stockCode":4581,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.849,"cashAndCashEquivalents":null,"assets":838618000000.0,"currentAssets":344783000000.0,"fixedAsset":493834000000.0,"tangibleFixedAssets":110892000000.0,"intangibleFixedAssets":189825000000.0,"investmentAndOtherAssets":193116000000.0,"liabilities":107305000000.0,"currentLiabilities":64246000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":43058000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":731313000000.0,"capitalStock":691217000000.0,"capital":30000000000.0,"capitalSurplus":null,"accumulatedEarnings":696665000000.0,"treasuryStock":-35447000000.0,"valuationAndConversionAdjustments":20375000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":211338000000.0,"costOfSales":77088000000.0,"grossProfit":134249000000.0,"sgaExpenses":116770000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":17569000000.0,"nonOperatingIncome":5661000000.0,"nonOperatingExpenses":2260000000.0,"interestExpense":34000000.0,"ordinaryProfit":20970000000.0,"extraordinaryGain":6102000000.0,"extraordinaryLoss":715000000.0,"incomeBeforeTax":26357000000.0,"incomeTaxes":7424000000.0,"netIncome":18933000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":17929000000.0,"comprehensiveIncome":10483000000.0,"eps":224.64,"dilutedEps":224.38,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/14","stockCode":4581,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":9354.0,"averageTemporaryStaff":667.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":42186000.0,"sharesOwendPercent":0.5281,"outstandingShares":null,"numberOfSubsidiary":37.0,"bps":8912.0,"equityRatio":0.834,"cashAndCashEquivalents":186941000000.0,"assets":853051000000.0,"currentAssets":355623000000.0,"fixedAsset":497428000000.0,"tangibleFixedAssets":112555000000.0,"intangibleFixedAssets":209980000000.0,"investmentAndOtherAssets":174891000000.0,"liabilities":111343000000.0,"currentLiabilities":66456000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":44887000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":741707000000.0,"capitalStock":693958000000.0,"capital":30000000000.0,"capitalSurplus":null,"accumulatedEarnings":699412000000.0,"treasuryStock":-35454000000.0,"valuationAndConversionAdjustments":17345000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":288527000000.0,"costOfSales":108337000000.0,"grossProfit":180190000000.0,"sgaExpenses":158923000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":22876000000.0,"operatingIncome":21460000000.0,"nonOperatingIncome":6619000000.0,"nonOperatingExpenses":3068000000.0,"interestExpense":118000000.0,"ordinaryProfit":25010000000.0,"extraordinaryGain":6133000000.0,"extraordinaryLoss":832000000.0,"incomeBeforeTax":30311000000.0,"incomeTaxes":8423000000.0,"netIncome":21887000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":20531000000.0,"comprehensiveIncome":9912000000.0,"eps":257.23,"dilutedEps":256.93,"dividendPerShare":null,"per":25.81,"roe":0.0288,"cashFlowFromOperatingActivities":41992000000.0,"depreciationAndCashflowFromOperatingActivities":11366000000.0,"cashFlowFromInvestingActivities":-107081000000.0,"cashFlowFromFinancialActivities":-11696000000.0,"changesInCashAndCashEquivalents":-76607000000.0,"列1":"asr","submitDate":"2020\/6\/26","stockCode":4581,"accountingYear":"第９期(自　2019年４月１日　至　2020年３月31日)","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.824,"cashAndCashEquivalents":null,"assets":858187000000.0,"currentAssets":352194000000.0,"fixedAsset":505993000000.0,"tangibleFixedAssets":111535000000.0,"intangibleFixedAssets":214171000000.0,"investmentAndOtherAssets":180286000000.0,"liabilities":121242000000.0,"currentLiabilities":62438000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":58804000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":736944000000.0,"capitalStock":693870000000.0,"capital":30000000000.0,"capitalSurplus":null,"accumulatedEarnings":699331000000.0,"treasuryStock":-35460000000.0,"valuationAndConversionAdjustments":13508000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":75023000000.0,"costOfSales":27837000000.0,"grossProfit":47185000000.0,"sgaExpenses":37838000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":9389000000.0,"nonOperatingIncome":1810000000.0,"nonOperatingExpenses":82000000.0,"interestExpense":31000000.0,"ordinaryProfit":11117000000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":300000000.0,"incomeBeforeTax":10818000000.0,"incomeTaxes":4130000000.0,"netIncome":6688000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6064000000.0,"comprehensiveIncome":3537000000.0,"eps":75.98,"dilutedEps":75.89,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/7","stockCode":4581,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":42625000.0,"sharesOwendPercent":0.5336,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.83,"cashAndCashEquivalents":203069000000.0,"assets":861043000000.0,"currentAssets":355246000000.0,"fixedAsset":505797000000.0,"tangibleFixedAssets":111486000000.0,"intangibleFixedAssets":215546000000.0,"investmentAndOtherAssets":178764000000.0,"liabilities":116886000000.0,"currentLiabilities":58058000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":58827000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":744157000000.0,"capitalStock":699310000000.0,"capital":30000000000.0,"capitalSurplus":13000000.0,"accumulatedEarnings":704727000000.0,"treasuryStock":-35430000000.0,"valuationAndConversionAdjustments":15047000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":145900000000.0,"costOfSales":52369000000.0,"grossProfit":93531000000.0,"sgaExpenses":77279000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":9429000000.0,"operatingIncome":16295000000.0,"nonOperatingIncome":2772000000.0,"nonOperatingExpenses":208000000.0,"interestExpense":64000000.0,"ordinaryProfit":18859000000.0,"extraordinaryGain":3000000.0,"extraordinaryLoss":470000000.0,"incomeBeforeTax":18393000000.0,"incomeTaxes":5983000000.0,"netIncome":12409000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":11294000000.0,"comprehensiveIncome":10802000000.0,"eps":141.51,"dilutedEps":141.34,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":19251000000.0,"depreciationAndCashflowFromOperatingActivities":7206000000.0,"cashFlowFromInvestingActivities":2922000000.0,"cashFlowFromFinancialActivities":-5777000000.0,"changesInCashAndCashEquivalents":16127000000.0,"列1":"q2r","submitDate":"2020\/11\/12","stockCode":4581,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.831,"cashAndCashEquivalents":null,"assets":861329000000.0,"currentAssets":354959000000.0,"fixedAsset":506370000000.0,"tangibleFixedAssets":110804000000.0,"intangibleFixedAssets":215661000000.0,"investmentAndOtherAssets":179903000000.0,"liabilities":116112000000.0,"currentLiabilities":57153000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":58958000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":745217000000.0,"capitalStock":698498000000.0,"capital":30000000000.0,"capitalSurplus":13000000.0,"accumulatedEarnings":703921000000.0,"treasuryStock":-35436000000.0,"valuationAndConversionAdjustments":17290000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":214300000000.0,"costOfSales":77523000000.0,"grossProfit":136776000000.0,"sgaExpenses":115805000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":20864000000.0,"nonOperatingIncome":4190000000.0,"nonOperatingExpenses":311000000.0,"interestExpense":100000000.0,"ordinaryProfit":24742000000.0,"extraordinaryGain":17000000.0,"extraordinaryLoss":597000000.0,"incomeBeforeTax":24162000000.0,"incomeTaxes":8261000000.0,"netIncome":15901000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":14235000000.0,"comprehensiveIncome":16541000000.0,"eps":178.35,"dilutedEps":178.12,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/10","stockCode":4581,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":9195.0,"averageTemporaryStaff":762.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":43145000.0,"sharesOwendPercent":0.5401,"outstandingShares":null,"numberOfSubsidiary":35.0,"bps":9129.95,"equityRatio":0.831,"cashAndCashEquivalents":215346000000.0,"assets":876923000000.0,"currentAssets":357731000000.0,"fixedAsset":519192000000.0,"tangibleFixedAssets":113194000000.0,"intangibleFixedAssets":216532000000.0,"investmentAndOtherAssets":189464000000.0,"liabilities":118516000000.0,"currentLiabilities":57666000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":60849000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":758406000000.0,"capitalStock":697598000000.0,"capital":30000000000.0,"capitalSurplus":12000000.0,"accumulatedEarnings":703036000000.0,"treasuryStock":-35450000000.0,"valuationAndConversionAdjustments":31105000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":281980000000.0,"costOfSales":106050000000.0,"grossProfit":175929000000.0,"sgaExpenses":156021000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":20251000000.0,"operatingIncome":19965000000.0,"nonOperatingIncome":6483000000.0,"nonOperatingExpenses":502000000.0,"interestExpense":156000000.0,"ordinaryProfit":25946000000.0,"extraordinaryGain":24000000.0,"extraordinaryLoss":2994000000.0,"incomeBeforeTax":22976000000.0,"incomeTaxes":7782000000.0,"netIncome":15194000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":13316000000.0,"comprehensiveIncome":28920000000.0,"eps":166.84,"dilutedEps":166.63,"dividendPerShare":null,"per":42.8,"roe":0.0185,"cashFlowFromOperatingActivities":42026000000.0,"depreciationAndCashflowFromOperatingActivities":14700000000.0,"cashFlowFromInvestingActivities":-1958000000.0,"cashFlowFromFinancialActivities":-11346000000.0,"changesInCashAndCashEquivalents":28404000000.0,"列1":"asr","submitDate":"2021\/6\/29","stockCode":4581,"accountingYear":"第10期(自　2020年４月１日　至　2021年３月31日)","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.831,"cashAndCashEquivalents":null,"assets":877471000000.0,"currentAssets":358656000000.0,"fixedAsset":518814000000.0,"tangibleFixedAssets":112653000000.0,"intangibleFixedAssets":220753000000.0,"investmentAndOtherAssets":185407000000.0,"liabilities":119628000000.0,"currentLiabilities":59204000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":60424000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":757842000000.0,"capitalStock":693644000000.0,"capital":30000000000.0,"capitalSurplus":22000000.0,"accumulatedEarnings":699057000000.0,"treasuryStock":-35435000000.0,"valuationAndConversionAdjustments":35230000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":63884000000.0,"costOfSales":24144000000.0,"grossProfit":39739000000.0,"sgaExpenses":37063000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":2676000000.0,"nonOperatingIncome":1625000000.0,"nonOperatingExpenses":268000000.0,"interestExpense":21000000.0,"ordinaryProfit":4033000000.0,"extraordinaryGain":3000000.0,"extraordinaryLoss":32000000.0,"incomeBeforeTax":4004000000.0,"incomeTaxes":2301000000.0,"netIncome":1703000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1179000000.0,"comprehensiveIncome":6953000000.0,"eps":14.78,"dilutedEps":14.75,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/11","stockCode":4581,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":45720000.0,"sharesOwendPercent":0.5572,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.841,"cashAndCashEquivalents":216698000000.0,"assets":885595000000.0,"currentAssets":361527000000.0,"fixedAsset":524068000000.0,"tangibleFixedAssets":116293000000.0,"intangibleFixedAssets":219748000000.0,"investmentAndOtherAssets":188026000000.0,"liabilities":121715000000.0,"currentLiabilities":61719000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":59995000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":763880000000.0,"capitalStock":705854000000.0,"capital":30000000000.0,"capitalSurplus":null,"accumulatedEarnings":696872000000.0,"treasuryStock":-21018000000.0,"valuationAndConversionAdjustments":39005000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":130161000000.0,"costOfSales":51637000000.0,"grossProfit":78523000000.0,"sgaExpenses":76210000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":9673000000.0,"operatingIncome":2313000000.0,"nonOperatingIncome":2391000000.0,"nonOperatingExpenses":481000000.0,"interestExpense":55000000.0,"ordinaryProfit":4223000000.0,"extraordinaryGain":2125000000.0,"extraordinaryLoss":79000000.0,"incomeBeforeTax":6269000000.0,"incomeTaxes":2320000000.0,"netIncome":3948000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2908000000.0,"comprehensiveIncome":12965000000.0,"eps":35.95,"dilutedEps":35.9,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":13938000000.0,"depreciationAndCashflowFromOperatingActivities":7347000000.0,"cashFlowFromInvestingActivities":-8307000000.0,"cashFlowFromFinancialActivities":-4823000000.0,"changesInCashAndCashEquivalents":1352000000.0,"列1":"q2r","submitDate":"2021\/11\/11","stockCode":4581,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0},{"edinetCode":"E25678","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.845,"cashAndCashEquivalents":null,"assets":875757000000.0,"currentAssets":365322000000.0,"fixedAsset":510434000000.0,"tangibleFixedAssets":116081000000.0,"intangibleFixedAssets":214373000000.0,"investmentAndOtherAssets":179980000000.0,"liabilities":115967000000.0,"currentLiabilities":59211000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":56755000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":759789000000.0,"capitalStock":707810000000.0,"capital":30000000000.0,"capitalSurplus":null,"accumulatedEarnings":698836000000.0,"treasuryStock":-21025000000.0,"valuationAndConversionAdjustments":32163000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":200051000000.0,"costOfSales":77846000000.0,"grossProfit":122205000000.0,"sgaExpenses":115071000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":7133000000.0,"nonOperatingIncome":4947000000.0,"nonOperatingExpenses":588000000.0,"interestExpense":109000000.0,"ordinaryProfit":11493000000.0,"extraordinaryGain":4114000000.0,"extraordinaryLoss":95000000.0,"incomeBeforeTax":15513000000.0,"incomeTaxes":5070000000.0,"netIncome":10442000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":8974000000.0,"comprehensiveIncome":12987000000.0,"eps":110.43,"dilutedEps":110.3,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/9","stockCode":4581,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25678","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":30000,"settlementDate":"2022\/3\/31","submitterName":"大正製薬ホールディングス株式会社","submitterNameEnglish":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","submitterNameKana":"タイショウセイヤクホールディングスカブシキガイシャ","location":"豊島区高田三丁目２４番１号","industory":"医薬品","corporateNumber":2010000000000.0}]